Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387660755> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4387660755 endingPage "9395" @default.
- W4387660755 startingPage "9388" @default.
- W4387660755 abstract "OBJECTIVE: The anticancer drug doxorubicin (DOX) is effective but is associated with complications such as hypothyroidism and cardiotoxicity. Pioglitazone (PIO), which is used to treat diabetes mellitus, has shown potential for treating hypothyroidism and cardiac dysfunction. Therefore, this study explores whether PIO can also ameliorate DOX-induced hypothyroidism and cardiotoxicity. MATERIALS AND METHODS: Forty female Wistar rats were separated into control and three treated groups (DOX, PIO, and DOX+PIO), and their blood samples were examined for the thyroid hormones, including thyroid-stimulating hormone (TSH), thyroxine in total and free forms (T4 and FT4, respectively), and triiodothyronine in total and free forms (T3 and FT3, respectively), and the cardiotoxicity biomarkers [troponin I, creatine kinase (CK), and creatine kinase-myocardial band (CK-MB)]. RESULTS: The control and PIO groups did not exhibit significant alterations in any of the examined hormones and markers. In contrast, in the DOX group, T4, FT4, T3, and FT3 levels decreased significantly, whereas troponin I, CK, and CK-MB levels increased significantly, but no significant changes were detected in TSH levels. PIO co-treatment ameliorated these effects of DOX significantly in FT4, FT3, and troponin I. CONCLUSIONS: PIO may provide protection against hypothyroidism and cardiotoxicity caused by DOX treatment, by significant reversal of FT4, FT3, and troponin I levels.https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract1.jpg." @default.
- W4387660755 created "2023-10-17" @default.
- W4387660755 creator A5009055174 @default.
- W4387660755 date "2023-10-01" @default.
- W4387660755 modified "2023-10-17" @default.
- W4387660755 title "Pioglitazone ameliorates doxorubicin-induced hypothyroidism and cardiotoxicity in rat models." @default.
- W4387660755 doi "https://doi.org/10.26355/eurrev_202310_33966" @default.
- W4387660755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37843360" @default.
- W4387660755 hasPublicationYear "2023" @default.
- W4387660755 type Work @default.
- W4387660755 citedByCount "0" @default.
- W4387660755 crossrefType "journal-article" @default.
- W4387660755 hasAuthorship W4387660755A5009055174 @default.
- W4387660755 hasConcept C115725540 @default.
- W4387660755 hasConcept C126322002 @default.
- W4387660755 hasConcept C134018914 @default.
- W4387660755 hasConcept C2776694085 @default.
- W4387660755 hasConcept C2777180221 @default.
- W4387660755 hasConcept C2777886399 @default.
- W4387660755 hasConcept C2778233292 @default.
- W4387660755 hasConcept C2778288131 @default.
- W4387660755 hasConcept C2778384471 @default.
- W4387660755 hasConcept C2781303535 @default.
- W4387660755 hasConcept C36880943 @default.
- W4387660755 hasConcept C500558357 @default.
- W4387660755 hasConcept C526584372 @default.
- W4387660755 hasConcept C555293320 @default.
- W4387660755 hasConcept C71315377 @default.
- W4387660755 hasConcept C71924100 @default.
- W4387660755 hasConceptScore W4387660755C115725540 @default.
- W4387660755 hasConceptScore W4387660755C126322002 @default.
- W4387660755 hasConceptScore W4387660755C134018914 @default.
- W4387660755 hasConceptScore W4387660755C2776694085 @default.
- W4387660755 hasConceptScore W4387660755C2777180221 @default.
- W4387660755 hasConceptScore W4387660755C2777886399 @default.
- W4387660755 hasConceptScore W4387660755C2778233292 @default.
- W4387660755 hasConceptScore W4387660755C2778288131 @default.
- W4387660755 hasConceptScore W4387660755C2778384471 @default.
- W4387660755 hasConceptScore W4387660755C2781303535 @default.
- W4387660755 hasConceptScore W4387660755C36880943 @default.
- W4387660755 hasConceptScore W4387660755C500558357 @default.
- W4387660755 hasConceptScore W4387660755C526584372 @default.
- W4387660755 hasConceptScore W4387660755C555293320 @default.
- W4387660755 hasConceptScore W4387660755C71315377 @default.
- W4387660755 hasConceptScore W4387660755C71924100 @default.
- W4387660755 hasIssue "19" @default.
- W4387660755 hasLocation W43876607551 @default.
- W4387660755 hasOpenAccess W4387660755 @default.
- W4387660755 hasPrimaryLocation W43876607551 @default.
- W4387660755 hasRelatedWork W200721289 @default.
- W4387660755 hasRelatedWork W2056974902 @default.
- W4387660755 hasRelatedWork W2144117633 @default.
- W4387660755 hasRelatedWork W2168137676 @default.
- W4387660755 hasRelatedWork W2169711162 @default.
- W4387660755 hasRelatedWork W2411999669 @default.
- W4387660755 hasRelatedWork W2414520037 @default.
- W4387660755 hasRelatedWork W2778141552 @default.
- W4387660755 hasRelatedWork W2971361148 @default.
- W4387660755 hasRelatedWork W419533798 @default.
- W4387660755 hasVolume "27" @default.
- W4387660755 isParatext "false" @default.
- W4387660755 isRetracted "false" @default.
- W4387660755 workType "article" @default.
!["OBJECTIVE: The anticancer drug doxorubicin (DOX) is effective but is associated with complications such as hypothyroidism and cardiotoxicity. Pioglitazone (PIO), which is used to treat diabetes mellitus, has shown potential for treating hypothyroidism and cardiac dysfunction. Therefore, this study explores whether PIO can also ameliorate DOX-induced hypothyroidism and cardiotoxicity. MATERIALS AND METHODS: Forty female Wistar rats were separated into control and three treated groups (DOX, PIO, and DOX+PIO), and their blood samples were examined for the thyroid hormones, including thyroid-stimulating hormone (TSH), thyroxine in total and free forms (T4 and FT4, respectively), and triiodothyronine in total and free forms (T3 and FT3, respectively), and the cardiotoxicity biomarkers [troponin I, creatine kinase (CK), and creatine kinase-myocardial band (CK-MB)]. RESULTS: The control and PIO groups did not exhibit significant alterations in any of the examined hormones and markers. In contrast, in the DOX group, T4, FT4, T3, and FT3 levels decreased significantly, whereas troponin I, CK, and CK-MB levels increased significantly, but no significant changes were detected in TSH levels. PIO co-treatment ameliorated these effects of DOX significantly in FT4, FT3, and troponin I. CONCLUSIONS: PIO may provide protection against hypothyroidism and cardiotoxicity caused by DOX treatment, by significant reversal of FT4, FT3, and troponin I levels.https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract1.jpg."](?object=%22OBJECTIVE%3A%20The%20anticancer%20drug%20doxorubicin%20(DOX)%20is%20effective%20but%20is%20associated%20with%20complications%20such%20as%20hypothyroidism%20and%20cardiotoxicity.%20Pioglitazone%20(PIO)%2C%20which%20is%20used%20to%20treat%20diabetes%20mellitus%2C%20has%20shown%20potential%20for%20treating%20hypothyroidism%20and%20cardiac%20dysfunction.%20Therefore%2C%20this%20study%20explores%20whether%20PIO%20can%20also%20ameliorate%20DOX-induced%20hypothyroidism%20and%20cardiotoxicity.%20MATERIALS%20AND%20METHODS%3A%20Forty%20female%20Wistar%20rats%20were%20separated%20into%20control%20and%20three%20treated%20groups%20(DOX%2C%20PIO%2C%20and%20DOX%2BPIO)%2C%20and%20their%20blood%20samples%20were%20examined%20for%20the%20thyroid%20hormones%2C%20including%20thyroid-stimulating%20hormone%20(TSH)%2C%20thyroxine%20in%20total%20and%20free%20forms%20(T4%20and%20FT4%2C%20respectively)%2C%20and%20triiodothyronine%20in%20total%20and%20free%20forms%20(T3%20and%20FT3%2C%20respectively)%2C%20and%20the%20cardiotoxicity%20biomarkers%20%5Btroponin%20I%2C%20creatine%20kinase%20(CK)%2C%20and%20creatine%20kinase-myocardial%20band%20(CK-MB)%5D.%20RESULTS%3A%20The%20control%20and%20PIO%20groups%20did%20not%20exhibit%20significant%20alterations%20in%20any%20of%20the%20examined%20hormones%20and%20markers.%20In%20contrast%2C%20in%20the%20DOX%20group%2C%20T4%2C%20FT4%2C%20T3%2C%20and%20FT3%20levels%20decreased%20significantly%2C%20whereas%20troponin%20I%2C%20CK%2C%20and%20CK-MB%20levels%20increased%20significantly%2C%20but%20no%20significant%20changes%20were%20detected%20in%20TSH%20levels.%20PIO%20co-treatment%20ameliorated%20these%20effects%20of%20DOX%20significantly%20in%20FT4%2C%20FT3%2C%20and%20troponin%20I.%20CONCLUSIONS%3A%20PIO%20may%20provide%20protection%20against%20hypothyroidism%20and%20cardiotoxicity%20caused%20by%20DOX%20treatment%2C%20by%20significant%20reversal%20of%20FT4%2C%20FT3%2C%20and%20troponin%20I%20levels.https%3A%2F%2Fwww.europeanreview.org%2Fwp%2Fwp-content%2Fuploads%2FGraphical-abstract1.jpg.%22){kind=link}